Oculoheel
Oculoheel, licence 80003136: inactive licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Biologische Heilmittel Heel GmbH
- NPN or DIN-HM
- 80003136
- Status
- Inactive licence
- Licence date
- 3 April 2007
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Homéopathique
If this product were sold in France
- Information
Homeopathic medicine in Canada, outside the scope of food supplements in France. Nutrient doses are not analysed.
Homéopathique. Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Staphisagria Potency : 45.0 mg D4 | 4.0 D | Not calculated |
| Spigelia anthelmia Potency : 60.0 mg D6 | 6.0 D | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium, Lactose Monohydrate
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Enfants | minimum: 1.0 Année(s) ; maximum: 5.0 Année(s) | Not specified | Not specified |
| Enfants | minimum: 6.0 Année(s) ; maximum: 11.0 Année(s) | Not specified | Not specified |
| Adultes | minimum: 12.0 Année(s) | Not specified | Not specified |
Uses authorised in Canada
Conjunctivitis, blepharitis, dacryocystitis (particularly chronic forms).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Doctor's supervision is necessary before administering to babies (0-12 months). If symptoms persist or worsen, consult a health care practitioner.
- Effets indésirables connus
In very rare cases, gastrointestinal complaints or skin reactions can occur even several days after use.
Source
Official Health Canada record, licence 80003136
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.